Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial - Reuters
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial Reuters
The pharmaceutical industry is heavily invested in developing new obesity treatments, with GLP-1 agonists showing significant efficacy, leading to a race for next-generation drugs with improved profiles.
Pfizer's entry into the monthly obesity shot market with a comparable side-effect profile to established weekly drugs like Wegovy significantly intensifies competition and offers a potentially more convenient option for patients.
The market for obesity treatments will become more competitive, potentially driving down prices or increasing accessibility, as a major player introduces a differentiated dosing schedule for an effective GLP-1 agonist.
- · Pfizer
- · Patients with obesity
- · Pharmaceutical innovation
- · Companies with less convenient weekly GLP-1s
- · Existing obesity treatment market share
Pfizer will gain market share in the rapidly expanding obesity treatment sector.
Increased competition could accelerate further development of even more effective and convenient obesity treatments.
Widespread access to effective obesity treatments could have long-term public health impacts, reducing comorbidities associated with obesity.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Reuters — Technology (Google News)